Biofilm microenvironment response nanoplatform synergistically degrades biofilm structure and relieves hypoxia for efficient sonodynamic therapy

Treatment of bacterial biofilms remains a great challenge in the clinic. Recently, ultrasound (US)-driven anti-microbial sonodynamic therapy (aSDT) has been considered as an emerging therapeutic strategy for the treat-ment of biofilm infections. However, the hypoxic microenvironment and restricted diffusion of sonosensitizers within biofilms substantially reduce the therapeutic efficacy of aSDT. Herein, a biofilm microenvironment-responsive nanoplatform was proposed to promote biofilm degradation and sonosensitizer penetration, and relieve the hypoxic microenvironment, thereby augmenting aSDT efficiency against bacterial biofilm infections. This nanoplatform was prepared by modifying manganese dioxide nanosheets (MNS) with alpha-amylase, poly-ethylene glycol (PEG), and chlorin e6 (Ce6) to form MNS-alpha-amylase/PEG-Ce6 nanosheets (MAPC). After delivery into biofilm-infected tissues, MAPC decompose in the acidic biofilm microenvironment to locally release alpha-amylase and Ce6. The alpha-amylase degrades the extracellular polymeric substances of biofilms to promote Ce6 penetration. In addition, the MNS catalyze the conversion of endogenously overproduced H2O2 into O2 in infected tissue and relieve the hypoxic microenvironment to further enhance antibiofilm efficacy of aSDT. Such biofilm degradation and hypoxia-relief enhanced aSDT show approximately 6.9 log units (99.99998%) reduction of bacteria within biofilms in vitro, and efficiently treat methicillin-resistant Staphylococcus aureus (MRSA) biofilms-infected mice. Overall, biofilm degradation improves sonosensitizer penetration and relieves the hyp-oxic biofilm microenvironment to enhance the effects of aSDT by MAPC. Thus, the use of this nanoplatform provides a promising strategy for combating bacterial biofilm-associated infections.

Automated summary

This study proposes a nanoplatform that improves the efficacy of bacterial biofilm treatment. The platform releases degrading enzymes and antimicrobial agents to promote biofilm degradation and enhance antimicrobial agent penetration in the biofilm microenvironment. Additionally, it relieves the hypoxic microenvironment, further enhancing the effects of sonodynamic therapy.